PTCH1 inactivation is the most frequently mutation in BCC, reported in 11–75% of sporadic BCCs [4,5,6,7,8,9,10], while activating mutations of SMO occur in 10–20% of BCCs [9,10,11]. This evidence concerns the gene SMO and skin basal cell carcinoma.